Pharma pay-for-delay concerns up again in Europe
This article was originally published in SRA
Executive Summary
The number of patent settlement deals signed between originator pharma companies and generics manufacturers that may violate EU anti-competition rules tripled in 2011 over the previous year, according to the European Commission's third monitoring report1.